Rybrevant Faspro (amivantamab and hyaluronidase-lpuj)
Multispecific antibody
Evidence outlook
Approved: Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also approved (1)
- Subcutaneous Rybrevant (amivantamab co-formulated with rHuPH20) with lazertinib, first-line EGFR-mutated NSCLC; monotherapy for exon 20 insertion NSCLC after platinum; Halozyme release dated 7 April 2025
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
PALOMA-3 NCT05388669 · Non-Small Cell Lung Cancer Registry: NCT05388669 | 3 | For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State (Pre-dose on Cycle 4 Day 1 (each cycle of 28 days)); For EU and Any Applicable Region: Observed Serum Concentration (Ctrough) of Amivantamab (Pre-dose on Cycle 2 Day 1 (each cycle of 28 days)); Area Under the Concentration (AUC) Time Curve of Amivantamab From Day 1 to Day 15 (AUC [Day 1-15]) of Cycle 2 (Cycle 2: Arm A: pre-dose, 24, 48, 72, 96, 168, and 360 hours (hrs) post-dose on Day 1; Arm B: pre-infusion, end of infusion (EOI)+10 minutes, EOI+2, EOI+6, EOI+24, EOI+48, EOI+72, EOI+168, and EOI+360 hrs post dose on Day 1) 2024-01-03 | Results posted on ClinicalTrials.gov. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Competitive landscape
Other EGFR x c-MET drugs
Amivantamab, ALK202, Bafisontamab, Pamvatamig, SKB571 and 3 more. Compare all 9 EGFR x c-MET drugs
This mechanism is crowded: 8 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Head and Neck Squamous Cell Carcinoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj): this drug | Approved | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| Cetuximab | Approved | Monoclonal antibody | EGFR | Partial signal | NCT00122460: Overall Survival Time (OS) (time from randomization to death or last day known to be alive, reported between day of first patient randomised, 21 Dec 2004, until cut-off date 12 Mar 2007): Cetuximab Plus Chemotherapy 10.1 months (95% CI 8.6 to 11.2) | Chemotherapy Alone 7.4 months (95% CI 6.4 to 8.3) | |
| Docetaxel (Taxotere) | Approved | Small molecule | Microtubules (tubulin) | not yet graded | No reviewed efficacy summary in this indication | |
| Nivolumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02105636: Overall Survival (OS) (From date of randomization to date of death (Up to approximately 18 months)): Nivolumab 3mg/kg 7.49 Months (95% CI 5.49 to 9.1) | Investigators Choice 5.06 Months (95% CI 4.04 to 6.05) | |
| Opdivo Qvantig | Approved | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Partial signal | NCT02358031: Primary endpoint, overall survival at a pre-specified interim analysis: pembrolizumab plus platinum/fluorouracil vs cetuximab plus platinum/fluorouracil, median 13.0 vs 10.7 months, HR 0.77; pembrolizumab alone vs cetuximab-chemotherapy in PD-L1 CPS >=1, HR 0.65 (95% CI 0.53 to 0.80) (KEYTRUDA label, KEYNOTE-048). | |
| Amivantamab | Phase 3 | Multispecific antibody | EGFR x c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| CPO301 | Phase 3 | Antibody–drug conjugate | EGFR | not yet graded | No reviewed efficacy summary in this indication | |
| NBTXR3 | Phase 3 | Nanoparticle | Hafnium-oxide nanoparticle radioenhancer | not yet graded | No reviewed efficacy summary in this indication | |
| Volrustomig | Phase 3 | Multispecific antibody | PD-1 x CTLA-4 | not yet graded | No reviewed efficacy summary in this indication | |
| Ordastobart | Phase 2/3 | Monoclonal antibody | OX40 (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab | Phase 2 | Multispecific antibody | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Ozuriftamab Vedotin | Phase 2 | Antibody–drug conjugate | ROR2 | Partial signal | No reviewed efficacy summary in this indication | |
| ALE.P02 | Phase 1/2 | Antibody–drug conjugate | Claudin-1 (CLDN1) | not yet graded | No reviewed efficacy summary in this indication | |
| Pepinemab | Phase 1/2 | Monoclonal antibody | SEMA4D | not yet graded | No reviewed efficacy summary in this indication | |
| Buparlisib | Discontinued | Small molecule | PI3K inhibitor (pan-class I) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent